MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer

A Study of Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01060033

Acronym

MRI

Enrollment

Registered

2010-02-01

Start date

2010-11-30

Completion date

2014-08-31

Last updated

2017-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Cervical Neoplasms

Keywords

Squamous cell cervical cancer

Brief summary

To detect differences in MR spectroscopy, diffusion weighted MR, diffusion tensor imaging (DTI) or dynamic contrast enhancement (DCE) MR imaging between primary cervical tumors and normal cervical tissue.

Detailed description

At our institution, all patients receiving external beam and/or brachytherapy as part of the treatment of primary cervical cancer receive CT, PET, and MRI simulation scans as standard of care. Brachytherapy patients also receive weekly T1/T2 weighted MR simulation scans as part of their treatment planning. We propose the use of additional MR sequences to the standard T1/T2 weighted MR simulation scans. The data obtained from these additional sequences will be used for improving tumor delineation and obtaining prognostic information.

Interventions

DEVICEMR Spectroscopy

DEVICEFat-Saturation and Diffusion-Weighted Imaging

DEVICEDynamic Contrast Enhancement MRI (MR-DCE)

DEVICEDiffusion Tensor Imaging (DTI)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DEVICE_FEASIBILITY

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must have biopsy-proven newly diagnosed squamous cell cervical cancer (FIGO clinical stages IB2-IVA). * Patients must be ≥ 18 years of age. * Patients must be able to receive standard radiation therapy (external beam radiation and brachytherapy) with or without chemotherapy. * Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least one year. * Patients must be scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging cervical cancer at Barnes-Jewish Hospital Clinical PET facility on the Siemens Biograph 40 True Point Tomograph Scanner or elsewhere in the WUSM Nuclear Medicine department using the quality controls instituted by Nuclear Medicine. * Patients must be able to give informed consent.

Exclusion criteria

* Patients with another known active malignancy. * Patients who have received treatment for any malignancy (with the exception of non-melanoma skin cancer) in the past 5 years. * Pregnant or breastfeeding patients. * Patients whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging. * Patients with contraindications to MRI scanning.

Design outcomes

Primary

Measure	Time frame
Differences in MR spectroscopy, diffusion weighted MR, diffusion tensor imaging (DTI) or dynamic contrast enhancement (DCE) MR imaging between primary cervical tumors and normal cervical tissue.	3 months

Secondary

Measure	Time frame
Determine whether MR-DCE or MR-FS or DTI can improve target delineation in primary cervical tumors.	3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026